- October 13, 2020
On October 13th, 2020, FDA hosted a virtual public meeting on Patient-Focused Drug Development for Systemic Sclerosis. FDA was interested in hearing patients’ perspectives on the impact of systemic sclerosis on daily life and patient views on treatment approaches.
In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket.
- The docket closes on December 15, 2020. FDA is interested in responses to the questions listed in the public docket.